Response
We, along with Drs Springer, Okonko, and Anker, speculate about the possibility that vagal stimulation improves survival in severe chronic heart failure (CHF) through the inhibition of the release of cytokines such as tumor necrosis factor-␣ (TNF-␣). 1 In an earlier cohort study, they showed that the plasma levels of the endotoxins, cytokines, and C-reactive protein were higher in edematous CHF patients than in stable CHF patients, suggesting that altered gut permeability with bacterial translocation and endotoxemia triggers immune activation in CHF patients during edematous episodes. 2 A recent clinical trial shows that pentoxifylline, an inhibitor of TNF-␣ synthesis at its transcriptional level, improved cardiac function and reduced the plasma level of TNF-␣ and C-reactive protein in CHF patients. 3 Although we did not measure the plasma concentration of endotoxins or cytokines, there was no significant difference between the treated and untreated CHF rats in the plasma level of C-reactive protein (Li et al, unpublished observation, 2003) .
At this stage, there is no supporting evidence that the immunomodulating agents 4 and the cholinergic antiinflammatory effects 5 improve survival in CHF. Therefore, to clarify the mechanisms for beneficial effects of vagal stimulation on CHF, further studies, including immunological assay, are needed.
